Growth Factor Therapy for Tissue Repair in St. Louis, MO

CDC PLACES vs. J5: two files, not one brochure

CDC PLACES (2023, crude) estimates 13.2% of adults in St. Louis have diagnosed diabetes — 1.2 points above the U.S. 12% figure. Census city-proper population is 301,578. If you are adding growth factor therapy, start with that epidemiology and with WPS Government Health Administrators (J5) — not with a “near me” clinic listing. Hawk Medical ships nationwide; Joe Bradley’s own practice uses the same product classes.

Epidemiology is not a protocol

• CDC PLACES (2023, crude) estimates 13.2% of adults in St. Louis have diagnosed diabetes — 1.2 points above the U.S. 12% figure. Adult arthritis here is 24.2% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. Separate 361 tissue, PRP, and CTP tickets before you market growth factor therapy in St. Louis. Mixing lanes is how recoupments start.
• Missouri is outside CDC's historical Diabetes Belt core, but the national 12% diabetes figure still applies as a planning baseline until a clinic uses its own payer mix. Clinics asking for regenerative inventory still have to separate HCT/P 361 homologous-use products from unapproved “stem cell” claims (FDA 21 CFR 1271).
• Non-opioid pain pathways (PRP, orthobiologics) still need diagnosis codes that justify the procedure. Missouri payers will not treat “patient prefers regenerative” as medical necessity.

Uninsured mix and Medicare CTPs in the same building

J5 reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in St. Louis is 13.2% or not. PLACES is planning data. The LCD is the claim.

Before the first growth factor therapy shipment